Related Experiment Video
Updated: May 18, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Severe infliximab-induced psoriasis treated with adalimumab switching
César Faillace1, Gleison Vieira Duarte, Rosângela Santos Cunha
1Rheumatology Dermatology Divisions, Clínica de Oncologia, Salvador, Bahia, Brazil.
Background:
Antitumor necrosis factor (anti-TNF) agents are a well-established treatment for various medical conditions, including psoriasis and psoriatic arthritis. However, anti-TNF agents may themselves induce psoriasis in some patients.
Methods:
The authors report two cases of patients with severe and refractory infliximab-induced psoriasis.
Results:
The patients had good clinical responses after switching to another TNF blocker.
Conclusion:
For severe cases, infliximab withdrawal combined with conventional immunosuppressive psoriasis drugs or with adalimumab may be a therapeutic option.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease III: Crohn's Disease
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease IV: Clinical Manifestations